Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab versus standard consolidation chemotherapy in pediatric high-risk first-relapse B-precursor acute lymphoblastic leukemia
2014-002476-92Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2015
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Blinatumomab consolidation with Standard-of-care consolidation chemotherapy (2 arms). Primary endpoint: Event-free survival. Started May 2015; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2014-002476-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002476-92.